This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Precedent exists for accelerating approval timelines during health emergencies such as the AIDs/HIV epidemic, where Compound S, a re-make of AZT, or azidothymidine, originally developed to fight cancer, became controversially fast-tracked after the discovery that it could block HIV activity.
Instead of being seen as just a series of numbers, financial statements, and outcomes, a successful revenue cycle should encompass the entire patient journey – which should continue to be the central focus and the heart of healthcare.
Erin Jospe, Chief Healthcare Advisor, World Wide Technology There has been a newfound effort to highlight and address the disparity in healthoutcomes for patients who belong to one or more marginalized communities.
Although it is well established that diversity improves outcomes and drives excellence, implementing diversity lags behind in many industries, including life sciences and healthcare. experience significant health disparities , including higher rates of chronic disease and premature death compared to the white population.
Patients can maintain regular contact with their healthcare providers, contributing to improved healthoutcomes and diminished healthcare disparities. This patient success story highlights how a proactive approach can make a profound difference in our patients' lives.
Perhaps the patient holds back vital information? Unasked questions almost always have consequences on patient satisfaction and even, potentially, their healthoutcomes. Addressing their burnout is critical for provider success and delivering patient-centered care that results in better healthoutcomes.
This translates to delayed diagnoses, advanced stages of disease at the time of discovery, and ultimately, poorer healthoutcomes. Building Partnerships : Collaborate with local hospitals, imaging centers, and patientadvocacy groups to expand the services available to FQHC patients.
Physicians and trial sponsors can also collaborate with dedicated advocacy organizations to spread awareness about clinical research opportunities within various sectors. Other notable patientadvocacy groups supporting patients with Muscular Dystrophy include the Muscular Dystrophy Association and Parent Project Muscular Dystrophy.
For many years, I’ve advocated for siloes to break down so that these organizations, all of which have mission statements that speak to benefit patient care and healthoutcomes, to more effective reach those Holy Grails.
Companies are profiting from sharing patient data with third parties, creating concerns over patient privacy and data ethics. How can we unify the system around the ultimate goal of better healthoutcomes? How do we transition from a data re-selling economy to a patient-benefitting insights economy?
Dunleavy adds $9M to budget to address food stamp, Medicaid backlog New study provides snapshot of increase in maternal deaths in Alaska Mental Health Trust Grants $1.6M
3] The FDA created the voluntary Breakthrough Devices Program to expedite the development, assessment, and review for premarket approval, 510(k) clearance, and de novo marketing authorization for devices designated as “breakthrough devices” to improve timely access for patients and providers. [4]
We organize all of the trending information in your field so you don't have to. Join 26,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content